AEON Biopharma to Present Botox Biosimilar Data at AAN 2026

Got story updates? Submit your updates here. ›

AEON Biopharma, a biopharmaceutical company advancing ABP-450 as a biosimilar to Botox, announced that it will present a poster at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago. The poster will showcase analytical data demonstrating that ABP-450 has an identical primary amino acid sequence to the reference product Botox, a key step in establishing biosimilarity.

Why it matters

The AAN Annual Meeting is the largest gathering of neurologists in the U.S., the specialty responsible for the majority of therapeutic botulinum toxin injections. AEON's presentation of analytical data supporting the biosimilarity of ABP-450 to Botox is an important milestone as the company seeks accelerated and full-label access to the lucrative U.S. therapeutic neurotoxin market, which exceeds $3 billion annually.

The details

AEON's analytical data show 93.5% - 99.3% peptide sequence coverage across BoNT/A1 and associated accessory proteins, with no variant peptides observed across multiple lots. This primary structure confirmation is a foundational component of biosimilar development and supports AEON's analytical similarity package for ABP-450. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau.

• The AAN Annual Meeting will take place April 18-22, 2026, in Chicago, IL.
• AEON's poster presentation is scheduled for Wednesday, April 22, 2026, from 11:45 am - 12:45 pm CT.

What’s next

The AAN 2026 presentation represents an important milestone for AEON as it seeks to establish the analytical similarity of ABP-450 to the reference product Botox, a key requirement under the FDA's biosimilar pathway. Following this presentation, AEON will continue to advance its clinical and regulatory strategy to achieve accelerated and full-label access to the U.S. therapeutic neurotoxin market.